Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Int J Hematol ; 112(5): 746-750, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-619933

ABSTRACT

COVID-19 is a new disease with many undescribed clinical manifestations. We report herein a case of severe immune thrombocytopenic purpura (ITP) in a critical COVID-19 patient. A patient presented a severe episode of immune thrombocytopenia (< 10 × 109/L) 20 days after admission for a critical COVID-19. This thrombocytopenia was associated with a life-threatening bleeding. Response to first-line therapies was delayed as it took up to 13 days after initiation of intravenous immunoglobulin and high-dose dexamethasone to observe an increase in platelet count. COVID-19 may be associated with late presenting severe ITP. Such ITP may also be relatively resistant to first-line agents. Hematological manifestations of COVID-19, such as the ones associated with life-threatening bleeding, must be recognized.


Subject(s)
Coronavirus Infections/complications , Pandemics , Pneumonia, Viral/complications , Purpura, Thrombocytopenic, Idiopathic/etiology , Betacoronavirus , COVID-19 , Combined Modality Therapy , Coronavirus Infections/drug therapy , Dexamethasone/therapeutic use , Hemorrhage/etiology , Humans , Immunoglobulins, Intravenous , Intracranial Hemorrhages/etiology , Male , Middle Aged , Pneumonia, Staphylococcal/etiology , Pneumonia, Ventilator-Associated/etiology , Pulmonary Atelectasis/etiology , Purpura, Thrombocytopenic, Idiopathic/drug therapy , Purpura, Thrombocytopenic, Idiopathic/therapy , Respiratory Distress Syndrome/etiology , Respiratory Distress Syndrome/therapy , SARS-CoV-2 , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL